|
WO2021029181A1
|
|
Clsp derivative incapable of being affected by clsp inhibiting substance, and clsp activity enhancing/protecting agent
|
|
WO2021006222A1
|
|
Nucleic acid carrier and method for administering nucleic acid
|
|
WO2020196873A1
|
|
Therapeutic agent for wolfram syndrome
|
|
JP2020167956A
|
|
Method for producing mature tissue, and method for producing organ
|
|
JP2020099533A
|
|
Bone surgery support device, support method, program and recording medium
|
|
WO2019077951A1
|
|
Antibody against muc1 or antigen-binding fragment thereof, gene encoding same, and use thereof
|
|
WO2019039595A1
|
|
Device and method for estimating cytodiagnostic category of cervix
|
|
JP2020026402A
|
|
Murf-1 expression inhibitor, and myopathy therapeutic agent
|
|
WO2018194120A1
|
|
Method for testing possibility of getting cancer and test reagent to be used therein
|
|
JP2019037170A
|
|
Methods for promoting target gene expression
|
|
JP2019035664A
|
|
System for testing possibility of relapse of liver cell cancer
|
|
JP2018033353A
|
|
Expression control nucleic acid molecule for control of gene expression and application thereof
|
|
JP2017100957A
|
|
Permanent depilatory
|
|
JP2017072523A
|
|
Cervical cancer test method and test reagent for use therein
|
|
JP2017057168A
|
|
Cell proliferation inhibitor, anticancer agent, and sensitivity enhancer for methyltransferase inhibitor
|
|
WO2016024628A1
|
|
Method for enhancing anticancer immunostimulating capacity of dendritic cells and use of same
|
|
WO2016009809A1
|
|
Expression-suppressing nucleic acid molecule for regulating expression of gene, and use thereof
|
|
JP2016006420A
|
|
Preparation method of saliva specimen
|
|
JP2016166160A
|
|
Porphyrin compound and use thereof
|
|
WO2015099122A1
|
|
Artificial mimic mirna for controlling gene expression, and use of same
|
